Loading...
Sign in to edit your profile (add interests, mentoring, photo, etc.)

    Peter Zage

    TitleAssociate Professor In Residence
    SchoolUniversity of California, San Diego
    DepartmentPediatrics
    Phone858-534-6494
    vCardDownload vCard

      Collapse Biography 
      Collapse Education and Training
      The Johns Hopkins UniversityBA1990
      Columbia University College of Physicians & SurgeonsMD, PhD1999

      Collapse Overview 

      Collapse Research 
      Collapse Research Activities and Funding
      The Role of Growth Factor Receptor Trafficking in Tumorigenesis
      NIH/NCI R01CA166749Apr 5, 2013 - Mar 31, 2018
      Role: Principal Investigator

      Collapse ORNG Applications 
      Collapse Featured Publications

      Collapse Bibliographic 
      Collapse Publications
      Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
      List All   |   Timeline
      1. Whittle SB, Smith V, Doherty E, Zhao S, McCarty S, Zage P. Overview and recent advances in the treatment of neuroblastoma. Expert Rev Anticancer Ther. 2017 Feb 01. PMID: 28142287.
        View in: PubMed
      2. Whittle SB, Patel K, Zhang L, Woodfield SE, Du M, Smith V, Zage P. The novel kinase inhibitor ponatinib is an effective anti-angiogenic agent against neuroblastoma. Invest New Drugs. 2016 Sep 1. PMID: 27586230.
        View in: PubMed
      3. Zage P, Whittle SB, Shohet JM. CD114: A New Member of the Neural Crest-Derived Cancer Stem Cell Marker Family. J Cell Biochem. 2016 Jul 18. PMID: 27428599.
        View in: PubMed
      4. Du M, Zhang L, Scorsone KA, Woodfield SE, Zage P. Nifurtimox Is Effective Against Neural Tumor Cells and Is Synergistic with Buthionine Sulfoximine. Sci Rep. 2016; 6:27458. PMID: 27282514.
        View in: PubMed
      5. Woodfield SE, Zhang L, Scorsone KA, Liu Y, Zage P. Binimetinib inhibits MEK and is effective against neuroblastoma tumor cells with low NF1 expression. BMC Cancer. 2016; 16(1):172. PMID: 26925841.
        View in: PubMed
      6. Whittle SB, Reyes S, Du M, Gireud M, Zhang L, Woodfield SE, Ittmann M, Scheurer ME, Bean AJ, Zage P. A Polymorphism in the FGFR4 Gene Is Associated With Risk of Neuroblastoma and Altered Receptor Degradation. J Pediatr Hematol Oncol. 2016 Mar; 38(2):131-8. PMID: 26840079.
        View in: PubMed
      7. Woodfield SE, Guo RJ, Liu Y, Major AM, Hollingsworth EF, Indiviglio S, Whittle SB, Mo Q, Bean AJ, Ittmann M, Lopez-Terrada D, Zage P. Neuroblastoma patient outcomes, tumor differentiation, and ERK activation are correlated with expression levels of the ubiquitin ligase UBE4B. Genes Cancer. 2016 Jan; 7(1-2):13-26. PMID: 27014418.
        View in: PubMed
      8. Zhang L, Scorsone K, Woodfield SE, Zage P. Sensitivity of neuroblastoma to the novel kinase inhibitor cabozantinib is mediated by ERK inhibition. Cancer Chemother Pharmacol. 2015 Nov; 76(5):977-87. PMID: 26407819.
        View in: PubMed
      9. Zhang L, Agarwal S, Shohet JM, Zage P. CD114 Expression Mediates Melanoma Tumor Cell Growth and Treatment Resistance. Anticancer Res. 2015 Jul; 35(7):3787-92. PMID: 26124323.
        View in: PubMed
      10. Zhang H, Dou J, Yu Y, Zhao Y, Fan Y, Cheng J, Xu X, Liu W, Guan S, Chen Z, shi Y, Patel R, Vasudevan SA, Zage P, Zhang H, Nuchtern JG, Kim ES, Fu S, Yang J. mTOR ATP-competitive inhibitor INK128 inhibits neuroblastoma growth via blocking mTORC signaling. Apoptosis. 2015 Jan; 20(1):50-62. PMID: 25425103; NIHMSID: NIHMS725698 [Available on 01/01/16].
        View in: PubMed
      11. Scorsone K, Zhang L, Woodfield SE, Hicks J, Zage P. The novel kinase inhibitor EMD1214063 is effective against neuroblastoma. Invest New Drugs. 2014 Oct; 32(5):815-24. PMID: 24832869.
        View in: PubMed
      12. Brown BS, Patanam T, Mobli K, Celia C, Zage P, Bean AJ, Tasciotti E. Etoposide-loaded immunoliposomes as active targeting agents for GD2-positive malignancies. Cancer Biol Ther. 2014 Jul; 15(7):851-61. PMID: 24755919; PMCID: PMC4100986.
      13. Aguilar S, Louis C, Hicks J, Zage P, Russell H. Congenital neuroblastoma in a neonate with isotretinoin embryopathy. J Pediatr Hematol Oncol. 2014 Mar; 36(2):e75-7. PMID: 23652876.
        View in: PubMed
      14. Stricker TP, Morales La Madrid A, Chlenski A, Guerrero L, Salwen HR, Gosiengfiao Y, Perlman EJ, Furman W, Bahrami A, Shohet JM, Zage P, Hicks MJ, Shimada H, Suganuma R, Park JR, So S, London WB, Pytel P, Maclean KH, Cohn SL. Validation of a prognostic multi-gene signature in high-risk neuroblastoma using the high throughput digital NanoString nCounter™ system. Mol Oncol. 2014 May; 8(3):669-78. PMID: 24560446; NIHMSID: NIHMS562546.
        View in: PubMed
      15. Sirisaengtaksin N, Gireud M, Yan Q, Kubota Y, Meza D, Waymire JC, Zage P, Bean AJ. UBE4B protein couples ubiquitination and sorting machineries to enable epidermal growth factor receptor (EGFR) degradation. J Biol Chem. 2014 Jan 31; 289(5):3026-39. PMID: 24344129; PMCID: PMC3908433.
      16. Zage P, Sirisaengtaksin N, Liu Y, Gireud M, Brown BS, Palla S, Richards KN, Hughes DP, Bean AJ. UBE4B levels are correlated with clinical outcomes in neuroblastoma patients and with altered neuroblastoma cell proliferation and sensitivity to epidermal growth factor receptor inhibitors. Cancer. 2013 Feb 15; 119(4):915-23. PMID: 22990745; NIHMSID: NIHMS396848.
        View in: PubMed
      17. Zage P, Louis CU, Cohn SL. New aspects of neuroblastoma treatment: ASPHO 2011 symposium review. Pediatr Blood Cancer. 2012 Jul 1; 58(7):1099-105. PMID: 22378620; NIHMSID: NIHMS604801.
        View in: PubMed
      18. Wolff JE, Rytting ME, Vats TS, Zage P, Ater JL, Woo S, Kuttesch J, Ketonen L, Mahajan A. Treatment of recurrent diffuse intrinsic pontine glioma: the MD Anderson Cancer Center experience. J Neurooncol. 2012 Jan; 106(2):391-7. PMID: 21858608; NIHMSID: NIHMS567623.
        View in: PubMed
      19. Zage P, Nolo R, Fang W, Stewart J, Garcia-Manero G, Zweidler-McKay PA. Notch pathway activation induces neuroblastoma tumor cell growth arrest. Pediatr Blood Cancer. 2012 May; 58(5):682-9. PMID: 21744479; NIHMSID: NIHMS320667.
        View in: PubMed
      20. Singh A, Rokes C, Gireud M, Fletcher S, Baumgartner J, Fuller G, Stewart J, Zage P, Gopalakrishnan V. Retinoic acid induces REST degradation and neuronal differentiation by modulating the expression of SCF(ß-TRCP) in neuroblastoma cells. Cancer. 2011 Nov 15; 117(22):5189-202. PMID: 21523764.
        View in: PubMed
      21. Stephen MD, Zage P, Waguespack SG. Gonadotropin-dependent precocious puberty: neoplastic causes and endocrine considerations. Int J Pediatr Endocrinol. 2011; 2011:184502. PMID: 21603196; PMCID: PMC3212801.
      22. Zage P, Graham TC, Zeng L, Fang W, Pien C, Thress K, Omer C, Brown JL, Zweidler-McKay PA. The selective Trk inhibitor AZ623 inhibits brain-derived neurotrophic factor-mediated neuroblastoma cell proliferation and signaling and is synergistic with topotecan. Cancer. 2011 Mar 15; 117(6):1321-91. PMID: 20960503.
        View in: PubMed
      23. Levy AG, Zage P, Akers LJ, Ghisoli ML, Chen Z, Fang W, Kannan S, Graham T, Zeng L, Franklin AR, Huang P, Zweidler-McKay PA. The combination of the novel glycolysis inhibitor 3-BrOP and rapamycin is effective against neuroblastoma. Invest New Drugs. 2012 Feb; 30(1):191-9. PMID: 20890785.
        View in: PubMed
      24. Das CM, Zage P, Taylor P, Aguilera D, Wolff JE, Lee D, Gopalakrishnan V. Chromatin remodelling at the topoisomerase II-beta promoter is associated with enhanced sensitivity to etoposide in human neuroblastoma cell lines. Eur J Cancer. 2010 Oct; 46(15):2771-80. PMID: 20886683; NIHMSID: NIHMS212200.
        View in: PubMed
      25. Richards KN, Zweidler-McKay PA, Van Roy N, Speleman F, Trevino J, Zage P, Hughes DP. Signaling of ERBB receptor tyrosine kinases promotes neuroblastoma growth in vitro and in vivo. Cancer. 2010 Jul 1; 116(13):3233-43. PMID: 20564646; NIHMSID: NIHMS219523.
        View in: PubMed
      26. Zage P, Zeng L, Palla S, Fang W, Nilsson MB, Heymach JV, Zweidler-McKay PA. A novel therapeutic combination for neuroblastoma: the vascular endothelial growth factor receptor/epidermal growth factor receptor/rearranged during transfection inhibitor vandetanib with 13-cis-retinoic acid. Cancer. 2010 May 15; 116(10):2465-75. PMID: 20225331.
        View in: PubMed
      27. Nilsson MB, Zage P, Zeng L, Xu L, Cascone T, Wu HK, Saigal B, Zweidler-McKay PA, Heymach JV. Multiple receptor tyrosine kinases regulate HIF-1alpha and HIF-2alpha in normoxia and hypoxia in neuroblastoma: implications for antiangiogenic mechanisms of multikinase inhibitors. Oncogene. 2010 May 20; 29(20):2938-49. PMID: 20208561.
        View in: PubMed
      28. Thress K, Macintyre T, Wang H, Whitston D, Liu ZY, Hoffmann E, Wang T, Brown JL, Webster K, Omer C, Zage P, Zeng L, Zweidler-McKay PA. Identification and preclinical characterization of AZ-23, a novel, selective, and orally bioavailable inhibitor of the Trk kinase pathway. Mol Cancer Ther. 2009 Jul; 8(7):1818-27. PMID: 19509272.
        View in: PubMed
      29. Zage P, Kletzel M, Murray K, Marcus R, Castleberry R, Zhang Y, London WB, Kretschmar C. Outcomes of the POG 9340/9341/9342 trials for children with high-risk neuroblastoma: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2008 Dec; 51(6):747-53. PMID: 18704922; NIHMSID: NIHMS123683.
        View in: PubMed
      30. Zage P, Reitman AJ, Seshadri R, Weinstein JL, Mets MB, Zeid JL, Greenwald MJ, Strauss LC, Goldman S. Outcomes of a two-drug chemotherapy regimen for intraocular retinoblastoma. Pediatr Blood Cancer. 2008 Mar; 50(3):567-72. PMID: 17729249.
        View in: PubMed
      31. Zhang M, Aguilera D, Das C, Vasquez H, Zage P, Gopalakrishnan V, Wolff J. Measuring cytotoxicity: a new perspective on LC50. Anticancer Res. 2007 Jan-Feb; 27(1A):35-8. PMID: 17352213.
        View in: PubMed
      32. Zhang M, Das C, Vasquez H, Aguilera D, Zage P, Gopalakrishnan V, Wolff JE. Predicting tumor cell repopulation after response: mathematical modeling of cancer cell growth. Anticancer Res. 2006 Jul-Aug; 26(4B):2933-6. PMID: 16886616.
        View in: PubMed
      33. Chlenski A, Liu S, Guerrero LJ, Yang Q, Tian Y, Salwen HR, Zage P, Cohn SL. SPARC expression is associated with impaired tumor growth, inhibited angiogenesis and changes in the extracellular matrix. Int J Cancer. 2006 Jan 15; 118(2):310-6. PMID: 16052522.
        View in: PubMed
      34. Liu S, Tian Y, Chlenski A, Yang Q, Zage P, Salwen HR, Crawford SE, Cohn SL. Cross-talk between Schwann cells and neuroblasts influences the biology of neuroblastoma xenografts. Am J Pathol. 2005 Mar; 166(3):891-900. PMID: 15743800; PMCID: PMC1602341.
      35. Yang Q, Zage P, Kagan D, Tian Y, Seshadri R, Salwen HR, Liu S, Chlenski A, Cohn SL. Association of epigenetic inactivation of RASSF1A with poor outcome in human neuroblastoma. Clin Cancer Res. 2004 Dec 15; 10(24):8493-500. PMID: 15623630.
        View in: PubMed
      36. David FS, Zage P, Marcantonio EE. Integrins interact with focal adhesions through multiple distinct pathways. J Cell Physiol. 1999 Oct; 181(1):74-82. PMID: 10457355.
        View in: PubMed
      37. Zage P, Marcantonio EE. The membrane proximal region of the integrin beta cytoplasmic domain can mediate oligomerization. Cell Adhes Commun. 1998 Jul; 5(5):335-47. PMID: 9789682.
        View in: PubMed